To Our New Jersey Life Sciences Community:
Welcome to another edition of the Weekender.
It’s been a stellar week for New Jersey’s EVER-GROWING life sciences community…
BioNJ Member Chromocell Corporation and Astellas Pharma have entered into a license and collaboration agreement valued at $500 million for the development and commercialization of therapeutics to treat neuropathic and other pain conditions.
BioNJ Member Bristol-Myers Squibb announced FDA approval of Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. The announcement marks the first and only FDA approval of a Regimen of two Immuno-Oncology agents in cancer.
BioNJ Member Oncobiologics secured financing that will support the expansion of the company’s facility, as well as continued development of the company’s proprietary BioSymphony™ Platform and advancement of its preclinical and clinical monoclonal antibody (“mAb”) biosimilar programs.
Hovione, a Portuguese company that makes pharmaceutical ingredients, is growing its New Jersey presence by expanding its East Windsor facility. The company’s plan will add 30,600 square feet to their 24,000 square foot facility and bolster its workforce by approximately 60 jobs.
BioNJ Member Amicus Therapeutics has completed its acquisition of Scioderm Inc. The purchase gives Amicus a biopharma company focused on treating diseases with high unmet need. Scioderm’s leading drug candidate is Zorblisa, a topical cream for Epidermolysis Bullosa — a chronic, genetic connective tissue disorder with no approved treatments.
NJBIZ just announced this year’s finalists for the Business of the Year awards. Congratulations to BioNJ Members Aaron Graff, President and CEO, Ferring Pharmaceuticals for being named as a finalist in the Corporate Citizen of the Year category and to Cornerstone Pharmaceuticals for being named as a finalist in the Emerging Business of the Year category.
Click here to read this week’s Weekender.